ImmunityBio (IBRX) Debt to Equity (2016 - 2025)
Historic Debt to Equity for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$0.6.
- ImmunityBio's Debt to Equity fell 6396.52% to -$0.6 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.6, marking a year-over-year decrease of 6396.52%. This contributed to the annual value of -$0.58 for FY2024, which is 11962.18% down from last year.
- Latest data reveals that ImmunityBio reported Debt to Equity of -$0.6 as of Q3 2025, which was down 6396.52% from -$0.54 recorded in Q2 2025.
- In the past 5 years, ImmunityBio's Debt to Equity registered a high of -$0.24 during Q1 2024, and its lowest value of -$2.0 during Q2 2021.
- For the 5-year period, ImmunityBio's Debt to Equity averaged around -$0.84, with its median value being -$0.6 (2025).
- As far as peak fluctuations go, ImmunityBio's Debt to Equity plummeted by 608535.3% in 2021, and later skyrocketed by 6854.09% in 2024.
- Over the past 5 years, ImmunityBio's Debt to Equity (Quarter) stood at -$1.26 in 2021, then surged by 30.73% to -$0.87 in 2022, then surged by 69.57% to -$0.26 in 2023, then crashed by 119.62% to -$0.58 in 2024, then decreased by 3.69% to -$0.6 in 2025.
- Its last three reported values are -$0.6 in Q3 2025, -$0.54 for Q2 2025, and -$0.5 during Q1 2025.